Tonix Pharmaceuticals Holding CORP DEF 14A proxy statements

Tonix Pharmaceuticals calls a May 7, 2026 virtual annual meeting to elect directors, ratify PwC, authorize reverse stock splits up to 1-for-250 over two years, and approve a 2026 Stock Incentive Plan.

Tonix Pharmaceuticals is asking shareholders to approve a reverse stock split, an amendment to its stock incentive plan, and a new employee stock purchase plan at the upcoming annual meeting.

Tonix Pharmaceuticals is asking shareholders to approve a reverse stock split and an increase in authorized shares at a special meeting on October 30, 2024, to meet Nasdaq listing requirements and for future corporate needs.

Tonix Pharmaceuticals is holding its annual meeting to vote on key proposals including a reverse stock split to regain Nasdaq compliance and repricing of outstanding warrants.